Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685529 · ClinicalTrials.gov registry record · Phase 2
Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00685529 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 24 participants.
The verdict
NCT00685529, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).
Interventions
- DRUG Arformoterol tartrate inhalation solution
- DRUG Racemic formoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685529
The ClinicalTrials.gov registry entry for NCT00685529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arformoterol tartrate inhalation solution is the first listed.
NCT00685529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685529 about?
NCT00685529 is a clinical study titled "Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT00685529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-04. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00685529?
The interventions under investigation include: Arformoterol tartrate inhalation solution (DRUG), Racemic formoterol (DRUG).
Who is sponsoring clinical trial NCT00685529?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.